# Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.

> **NCT00385138** · PHASE3 · TERMINATED · sponsor: **The Medicines Company** · enrollment: 5364 (actual)

## Conditions studied

- Atherosclerosis
- Acute Coronary Syndrome (ACS)

## Interventions

- **DRUG:** Cangrelor
- **DRUG:** clopidogrel
- **DRUG:** Placebo bolus & placebo infusion
- **DRUG:** Placebo capsules - end of PCI
- **DRUG:** Placebo capsules - end of infusion

## Key facts

- **NCT ID:** NCT00385138
- **Lead sponsor:** The Medicines Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-09
- **Primary completion:** 2009-05
- **Final completion:** 2010-06
- **Target enrollment:** 5364 (ACTUAL)
- **Why stopped:** Insufficient evidence of the clinical effectiveness of cangrelor
- **Last updated:** 2014-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00385138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00385138, "Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00385138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*